Neural Stem Cells Show Early Promise in Phase 1 Trial as Treatment for Parkinson’s
Patients with moderate-to-severe Parkinson’s disease who received human neural stem cells in their brain as part of a Phase 1 trial are performing better at six months than they were at the start of the study. Also, all patients are meeting the trial’s primary goal of safety, according to a…